VEGFA and neoplasm: On the basis of previous studies that have targeted VEGFA in breast cancer [14,15,16,17], we tested the tumor-suppressive effects of bevacizumab, a humanized Vascular Endothelial Growth Factor A (VEGFA) antagonist and docetaxel, which was chosen with the consideration of treatment history on PDX models derived from PT12 (Figure 3).